Pharmaceutics (Aug 2024)

Passive Immunotherapy of Cynomolgus Monkeys with Anti-Rotavirus IgY

  • Gentil Arthur Bentes,
  • Juliana Rodrigues Guimarães,
  • Eduardo de Mello Volotão,
  • Natália Maria Lanzarini,
  • Alexandre dos Santos da Silva,
  • Noemi Rovaris Gardinali,
  • Renato Sergio Marchevsky,
  • José Paulo Gagliardi Leite,
  • Jaqueline Mendes de Oliveira,
  • Marcelo Alves Pinto

DOI
https://doi.org/10.3390/pharmaceutics16091149
Journal volume & issue
Vol. 16, no. 9
p. 1149

Abstract

Read online

Immunoglobulins Y (IgY) purified from egg yolks of hens represents an attractive, cost-effective alternative for the development of new diagnostic and therapeutic platforms. In this study, we evaluated the therapeutic efficacy of rotavirus-specific IgY in a cynomolgus monkey (Macaca fascicularis) model. Animals were experimentally infected with human rotavirus Group A (RVA), the most common cause of severe acute diarrhoea among young children worldwide. Animals were administered human RVA (3.1 × 107 FFU/mL) by oral gavage, challenged with 2.5 mg of anti-RVA IgY orally, and monitored for five days according to clinical, haematological and biochemical parameters; serum electrolyte levels; viral shedding; and histopathological changes. Immunotherapy with anti-RVA IgY had a protective effect against severe rotavirus-induced enteritis in four of the ten treated monkeys, as evidenced by histopathological findings. Although only one animal had diarrhoea, all but one exhibited virus shedding regardless of the treatment.

Keywords